News

Video

February 19, 2025

Navigating Treatment Options in Advanced NSCLC with HER2 Mutations

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos

Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

Julie M. Vose, MD, MBA

6369343864112

Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health

Related Content

Pretreated R/R MCL | Image Credit: © Corona Borealis - stock.adobe.com

March 13th 2025

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

March 13th 2025

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

Global Oncology | Image Credit: © Katsyarina – stock.adobe.com

March 13th 2025

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

March 12th 2025

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

Endometrial Cancer | Image Credit: © Cornflakesei – stock.adobe.com

March 13th 2025

Palbociclib/Letrozole Combo Boosts PFS in ER+ Advanced/Recurrent Endometrial Cancer

Navtemadlin Plus Ruxolitinib in Myelofibrosis | Image Credit:© LASZLO - stock.adobe.com

March 13th 2025

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis

Related Content

Pretreated R/R MCL | Image Credit: © Corona Borealis - stock.adobe.com

March 13th 2025

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

March 13th 2025

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

Global Oncology | Image Credit: © Katsyarina – stock.adobe.com

March 13th 2025

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

March 12th 2025

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

Endometrial Cancer | Image Credit: © Cornflakesei – stock.adobe.com

March 13th 2025

Palbociclib/Letrozole Combo Boosts PFS in ER+ Advanced/Recurrent Endometrial Cancer

Navtemadlin Plus Ruxolitinib in Myelofibrosis | Image Credit:© LASZLO - stock.adobe.com

March 13th 2025

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis

Latest Conference Coverage

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.